Molecular Diagnostics tests in Dubai & UAE

Compare available Molecular Diagnostics tests, their listed prices and the information provided for each option. Test selection and preparation should be discussed with your clinician.

Tests in this category

781

Listed price range

550.00–150,000.00 AED

Clinical preparation

Confirm test-specific instructions with your clinician or laboratory.

Compare available tests

Molecular Diagnostics test prices

Showing 436–450 of 781 matching tests.

Molecular Diagnostics diagnostic tests, details, and listed prices
Test and description	Specimen	Typical duration	Price	Options
TEST-2333 KRAS Mutation (Codons 12 & 13) Analysis Test This test identifies specific mutations in the KRAS gene (codons 12 and 13) within a tissue sample.	Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block	5 working days from FFPE block receipt	1,500.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["KRAS gene mutations (Codons 12 & 13)", "Mutant allele frequency"] Parameters [] Preparation [] Indications ["Metastatic colorectal adenocarcinoma", "Prior to initiating anti-EGFR therapy"] Measurement technique Confirm with laboratory Codes LOINC: 21663-7 ICD-10: C18.9 Clinical summary This test identifies specific mutations in the KRAS gene (codons 12 and 13) within a tissue sample.
TEST-1454 KRAS Mutation Screening (Codons 12 & 13) Test This test identifies specific mutations in the KRAS gene (codons 12 and 13) within tumor tissue.	Formalin-Fixed Paraffin-Embedded (FFPE) Tumor Tissue (Archival Specimen)	7–8 Business Days from receipt of specimen	1,400.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["KRAS gene mutations (Codons 12 & 13)", "Somatic mutations"] Parameters [] Preparation ["No fasting or medication adjustments are necessary.", "No special dietary restrictions are required."] Indications ["Guiding anti-EGFR therapy in metastatic colorectal cancer", "Prognosis in pancreatic, lung, and gynecologic malignancies", "Tailoring targeted treatment"] Measurement technique Confirm with laboratory Codes LOINC: 21572-2 ICD-10: C18.9 Clinical summary This test identifies specific mutations in the KRAS gene (codons 12 and 13) within tumor tissue.
TEST-4670 KRT16 Gene Palmoplantar Keratoderma, Nonepidermolytic, Focal Genetic Test This test identifies pathogenic variants in the KRT16 gene associated with focal nonepidermolytic palmoplantar keratoderma.	Peripheral Blood, Extracted DNA, or FTA Card	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the KRT16 gene"] Parameters [] Preparation ["Mandatory pre-test genetic counselling session", "Pedigree chart of affected family members required"] Indications ["Suspected diagnosis of focal nonepidermolytic palmoplantar keratoderma", "Family history of KRT16-related keratoderma"] Measurement technique Confirm with laboratory Codes LOINC: 94321-1 ICD-10: Q82.8 Clinical summary This test identifies pathogenic variants in the KRT16 gene associated with focal nonepidermolytic palmoplantar keratoderma.
TEST-4660 KRT17 Gene Pachyonychia Congenita Type 2 Genetic Test This test identifies pathogenic variants in the KRT17 gene associated with Pachyonychia Congenita Type 2.	Peripheral Whole Blood – EDTA (2–5 mL)	3–4 Weeks (21–28 Calendar Days)	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the KRT17 gene"] Parameters [] Preparation ["No special preparation required", "Inform phlebotomist if taking blood-thinning medications", "Avoid heavy lotions or creams on venipuncture site"] Indications ["Clinical suspicion of Pachyonychia Congenita Type 2", "Family history of Pachyonychia Congenita Type 2"] Measurement technique Confirm with laboratory Codes LOINC: 21636-6 ICD-10: Q82.8 Clinical summary This test identifies pathogenic variants in the KRT17 gene associated with Pachyonychia Congenita Type 2.
TEST-5116 LAMA3 Gene Sequencing for Generalized Atrophic Benign Epidermolysis Bullosa (Junctional EB) Test This test identifies genetic variants in the LAMA3 gene associated with generalized atrophic benign epidermolysis bullosa.	Peripheral Whole Blood (EDTA), Buccal Swab, or FTA Card	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["LAMA3 gene variants", "Single nucleotide variants", "Small insertions", "Small deletions"] Parameters [] Preparation ["No specific fasting required", "Do not discontinue prescribed medication without consulting your doctor"] Indications ["Suspected generalized atrophic benign epidermolysis bullosa", "Family history of junctional EB", "Carrier testing", "Recurrence risk assessment"] Measurement technique Confirm with laboratory Codes LOINC: 9489-2 ICD-10: Q81.9 Clinical summary This test identifies genetic variants in the LAMA3 gene associated with generalized atrophic benign epidermolysis bullosa.
TEST-3633 LAMB2 Gene Nephrotic Syndrome Type 5 Genetic Test This test identifies pathogenic mutations in the LAMB2 gene associated with Pierson syndrome (Nephrotic Syndrome Type 5).	Peripheral whole blood or FTA card (dried blood spot)	3–4 weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic mutations in the LAMB2 gene", "Coding exons and splice sites of the LAMB2 gene"] Parameters [] Preparation ["No specific fasting required.", "No medication adjustments needed prior to testing."] Indications ["Diagnosis of Nephrotic Syndrome Type 5 (Pierson syndrome)", "Confirmation of LAMB2 gene mutations", "Genetic counselling for affected families"] Measurement technique Confirm with laboratory Codes LOINC: 93776-6 ICD-10: N04.5 Clinical summary This test identifies pathogenic mutations in the LAMB2 gene associated with Pierson syndrome (Nephrotic Syndrome Type 5).
TEST-6260 LDLR Gene Hypercholesterolemia due to LDL‑Receptor Disorder (Autosomal Dominant) Genetic Test This genetic test identifies pathogenic variants in the LDLR gene associated with autosomal dominant familial hypercholesterolemia.	Peripheral Whole Blood	3 – 4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the LDLR gene", "Single-nucleotide variants", "Small insertions or deletions", "Splice-site alterations"] Parameters [] Preparation ["No specific fasting required", "Do not discontinue prescribed medications"] Indications ["Diagnosis of familial hypercholesterolemia", "Cascade screening of family members", "Personalized therapy selection (statins, PCSK9 inhibitors)", "Differentiation of genetic vs. acquired hyperlipidemia"] Measurement technique Confirm with laboratory Codes LOINC: 46871-8 ICD-10: E78.01 Clinical summary This genetic test identifies pathogenic variants in the LDLR gene associated with autosomal dominant familial hypercholesterolemia.
TEST-455 Legal Paternity DNA Test This test determines biological parentage by analyzing specific DNA markers (STR loci) in blood samples from the child and alleged father.	Peripheral Whole Blood (5 mL EDTA)	10 Days (Expedited 5-Day Option Available)	5,000.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Short Tandem Repeat (STR) loci", "Probability of Paternity"] Parameters [] Preparation [] Indications ["Legal disputes regarding parentage", "Immigration requirements", "Inheritance claims", "Custody cases"] Measurement technique Confirm with laboratory Codes LOINC: 93550-5 ICD-10: Z02.81, Z31.82, Z14.8 Clinical summary This test determines biological parentage by analyzing specific DNA markers (STR loci) in blood samples from the child and alleged father.
TEST-2383 Leukemia Genetic Profile Test This test qualitatively detects six specific genetic mutations associated with leukaemia using real-time PCR.	Blood (peripheral whole blood) or Bone Marrow	2–3 business days	1,500.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Specific genetic mutations associated with leukaemia"] Parameters [] Preparation ["Inform physician about current medications", "No fasting required for blood draw", "Follow pre-procedure instructions if bone marrow aspiration is needed"] Indications ["Confirmation of leukaemia subtype", "Prognostic risk stratification", "Selection of targeted therapy"] Measurement technique Confirm with laboratory Codes LOINC: 98531-5 ICD-10: C95.9, Z01.818 Clinical summary This test qualitatively detects six specific genetic mutations associated with leukaemia using real-time PCR.
TEST-4414 LGI1 Gene Epilepsy, Familial Temporal Lobe Epilepsy Type 1 Test This test identifies pathogenic variants in the LGI1 gene associated with autosomal dominant familial temporal lobe epilepsy.	Peripheral whole blood (EDTA) or extracted genomic DNA	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["LGI1 gene pathogenic variants", "Copy Number Variations (CNVs) in LGI1"] Parameters [] Preparation ["No specific fasting required", "Inform lab of any anti-seizure medications"] Indications ["Suspected autosomal dominant familial temporal lobe epilepsy", "Diagnosis confirmation", "Family screening"] Measurement technique Confirm with laboratory Codes LOINC: 81321-3 ICD-10: G40.2 Clinical summary This test identifies pathogenic variants in the LGI1 gene associated with autosomal dominant familial temporal lobe epilepsy.
TEST-1426 Liquid Biopsy Cell-Free KRAS Mutation Analysis (cfDNA KRAS) Test This test identifies the presence and specific type of KRAS gene mutations in circulating tumor DNA (ctDNA) within a patient's blood plasma.	Plasma (from peripheral blood)	5–7 working days	2,400.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["KRAS gene mutations", "Circulating tumor DNA (ctDNA)"] Parameters [{"name": "KRAS Mutation Status", "reference_range": "Negative / Positive (Specific Mutation)"}] Preparation ["A doctor’s prescription is mandatory", "Avoid heavy meals and strenuous exercise 2 hours before blood collection", "Inform phlebotomist of any blood-thinning medications"] Indications ["Monitoring treatment response in cancer patients", "Detecting resistance mutations", "Guiding targeted therapy selection (e.g., anti-EGFR)", "Non-invasive cancer monitoring"] Measurement technique Confirm with laboratory Codes LOINC: 88233-7 ICD-10: C80.0, C18.9, C34.9 Clinical summary This test identifies the presence and specific type of KRAS gene mutations in circulating tumor DNA (ctDNA) within a patient's blood plasma.
TEST-1432 Liquid Biopsy Cell‑Free BRAF Mutation Analysis Test This test detects the presence of specific BRAF V600E/K mutations in circulating tumor DNA (ctDNA) within a blood sample.	Peripheral Blood Plasma (ctDNA)	5–7 Working Days	2,400.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["BRAF V600E mutation", "BRAF V600K mutation", "Circulating cell-free tumor DNA (ctDNA)"] Parameters [] Preparation ["No fasting is required.", "Continue all prescribed medications unless your oncologist specifically instructs otherwise."] Indications ["Monitoring oncologic therapy", "Early recurrence detection", "Guiding targeted therapy selection"] Measurement technique Confirm with laboratory Codes LOINC: 92821-8 ICD-10: C43.9, Z85.9 Clinical summary This test detects the presence of specific BRAF V600E/K mutations in circulating tumor DNA (ctDNA) within a blood sample.
TEST-1430 Liquid Biopsy Cell‑Free EGFR Mutation Analysis (T790M, L858R, Exon 19 Deletion) Test This test identifies specific mutations in the EGFR gene within cell-free DNA from a blood sample, aiding in the selection of targeted therapies for non-small cell lung cancer.	Peripheral blood (cell-free DNA stabilisation tube)	5–7 working days	2,000.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["EGFR T790M mutation", "EGFR L858R mutation", "EGFR Exon 19 deletion"] Parameters [] Preparation ["No fasting required", "Continue prescribed medications", "Drink water to stay hydrated", "Avoid heavy physical exertion 30 minutes before collection if possible"] Indications ["Diagnosis of NSCLC", "Monitoring treatment response", "Detecting resistance mutations"] Measurement technique Confirm with laboratory Codes LOINC: 94311-1 ICD-10: C34.9 Clinical summary This test identifies specific mutations in the EGFR gene within cell-free DNA from a blood sample, aiding in the selection of targeted therapies for non-small cell lung cancer.
TEST-1428 Liquid Biopsy Cell‑Free PAN RAS (KRAS, NRAS) Mutation Panel Test This test evaluates for the presence of mutations in the KRAS and NRAS genes within cell-free DNA isolated from peripheral blood.	Peripheral Blood (plasma cell-free DNA)	5–7 business days	3,600.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["KRAS gene mutations", "NRAS gene mutations", "Cell-free DNA (cfDNA)"] Parameters [] Preparation ["Do not discontinue, pause, or alter any prescribed medication without explicit instruction from your treating physician."] Indications ["Patients with known or suspected colorectal, lung, or pancreatic cancer", "Guiding targeted therapy selection (anti-EGFR)", "Monitoring treatment response"] Measurement technique Confirm with laboratory Codes LOINC: 94488-8 ICD-10: C80.1 Clinical summary This test evaluates for the presence of mutations in the KRAS and NRAS genes within cell-free DNA isolated from peripheral blood.
TEST-1033 Liquid Biopsy Chemosensitivity Test This test evaluates circulating tumor DNA (ctDNA) in a blood sample to predict chemotherapy response.	Peripheral Whole Blood (EDTA tube)	10 Business Days	4,000.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Circulating Tumor DNA (ctDNA)", "Chemosensitivity mutations"] Parameters [] Preparation ["No fasting required", "Continue all prescribed medications unless instructed otherwise by your doctor"] Indications ["Personalized chemotherapy selection", "Guiding cancer treatment decisions"] Measurement technique Confirm with laboratory Codes LOINC: 96701-7 ICD-10: Z51.11 Clinical summary This test evaluates circulating tumor DNA (ctDNA) in a blood sample to predict chemotherapy response.

Category overview

Molecular Diagnostics: overview

When complex health questions arise, evaluating your health at the cellular level provides the definitive clarity necessary for proactive care. At DNA Labs UAE, our Molecular Diagnostics services harness the power of advanced nucleic acid amplification and real-time PCR technologies to detect diseases with unparalleled sensitivity. From identifying viral loads to pinpointing genetic markers, our specialized molecular testing in the UAE gives your healthcare provider the precise data needed to customize your medical strategy. Trust in one of the leading diagnostic labs in Dubai and the UAE to process your samples with rigorous confidentiality and exceptionally fast, accurate turnaround times. Step forward with absolute confidence. View our molecular diagnostics profiles below, request a seamless home sample collection, or contact our specialized team to book your test.

Before booking

Use the test details as a conversation starter

The right diagnostic option depends on your reason for testing and individual circumstances. Check the listed specimen and timing, then confirm any preparation requirements with the ordering clinician or laboratory before collection.

Explore this area

Molecular Diagnostics tests in Dubai & UAE

Molecular Diagnostics test prices

Molecular Diagnostics: overview

Use the test details as a conversation starter

Related Molecular Diagnostics categories